9. The combination according to any one of claims 1 to 4, wherein the compound A is *N*-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, or an N-oxide, a hydrate, a solvate, or a salt thereof.

10. The combination according to any one of claims 1 to 9, further comprising cisplatin.

11. The combination according to any one of claims 1 to 10 for the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

12. Use of a combination according to any one of claims 1 to 10 for the preparation of a medicament for the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

13. A method of treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer in a subject, comprising administering to said subject a therapeutically effective amount of a combination according to any one of claims 1 to 10.

14. A kit comprising a combination of :
component A : one or more compounds A, as defined in any one of claims 1, 5, 6, 7, 8, and 9;
and
component B : one or more mitotic inhibitors, including docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine;

and, optionally, one or more further pharmaceutical agents C; in which optionally all or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

15. The kit according to claim 14, wherein the mitotic inhibitor is selected from docetaxel, paclitaxel and the optional pharmaceutical agent C is cisplatin.

9. The combination according to any one of claims 1 to 4, wherein the compound A is *N*-cyclopropyl-4-{6-(2,3-difluoro-4-methoxyphenoxy)-8-[(tetrahydro-2*H*-pyran-4-ylmethyl)amino]imidazo[1,2-*b*]pyridazin-3-yl}-2-methylbenzamide, or an N-oxide, a hydrate, a solvate, or a salt thereof.

10. The combination according to any one of claims 1 to 9, further comprising cisplatin.

11. The combination according to any one of claims 1 to 10 for use in the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

12. The use of a combination according to any one of claims 1 to 10 in the manufacture of a medicament for the treatment or prophylaxis of pancreatic cancer, glioblastoma, ovarian cancer, non-small cell lung carcinoma, breast cancer and/or gastric cancer.

13. A kit comprising a combination of :
component A : one or more compounds A, as defined in any one of claims 1, 5, 6, 7, 8, and 9;
and
component B : one or more mitotic inhibitors, including docetaxel, paclitaxel, vinblastine, vincristine, vindesine, and vinorelbine;
and, optionally, one or more further pharmaceutical agents C; in which optionally all or either of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially.

14. The kit according to claim 13, wherein the mitotic inhibitor is selected from docetaxel, paclitaxel and the optional pharmaceutical agent C is cisplatin.